Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin - Novo Nordisk

Next Previous
Drug Profile

Somatropin - Novo Nordisk

Alternative Names: NN-1610; NN-220; Norditropin; Norditropin cartridge; Norditropin FlexPro; Norditropin NordiFlex; Norditropin NordiLet; Norditropin NordiPen; Norditropin S; Norditropin SimpleXx

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
  • Mechanism of Action Human growth hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short stature; Female infertility; Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
  • Discontinued Female infertility; Fracture; Nutrition disorders

Most Recent Events

  • 01 Mar 2022 Launched for Short stature (In children) in France (SC) before March 2022 (NCT05308927)
  • 09 Jul 2019 Discontinued - Phase-III for Short stature (In children) in South Korea (SC) as no development reported after, December 2014 (NCT01778023)
  • 12 Jul 2018 Novo Nordisk completes a phase III trial in Short Stature (In children with Noonan Syndrome) in Japan (NCT01927861)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top